Compare IDEXX Laboratories, Inc. (IDXX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? IDEXX Laboratories, Inc. trades at $556.84 (market cap $44.48B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $117.84. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | QQQE | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $122.72 |
52-Week Low | $520.87 | $96.06 |
Enterprise Value | $45.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
QQQE trades at $116.70, down 0.09% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF offers equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its defensive appeal amid market shifts, with SpaceX's imminent Nasdaq-100 inclusion potentially driving passive inflows.
The outlook balances diversification benefits against market volatility risks. Equal weighting provides stability if mega-cap tech underperforms, but the bearish technical trend and neutral oscillators suggest near-term caution. Investors seeking Nasdaq exposure with lower single-stock risk may find QQQE attractive, though monitoring index rebalancing impacts is crucial.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
